About the Authors

William Pao

Contributed equally to this work with: William Pao, Vincent A Miller

To whom correspondence should be addressed. E-mail: paow@mskcc.org

Affiliations Program in Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America, Thoracic Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

Vincent A Miller

Contributed equally to this work with: William Pao, Vincent A Miller

Affiliation Thoracic Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

Katerina A Politi

Affiliation Program in Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

Gregory J Riely

Affiliation Thoracic Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

Romel Somwar

Affiliation Program in Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

Maureen F Zakowski

Affiliation Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

Mark G Kris

Affiliation Thoracic Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

Harold Varmus

Affiliation Program in Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

Competing Interests

VAM has received research funding from Genentech (co-developer of erlotinib) and has received honoraria from AstraZeneca (maker of gefitinib) for consultancy. MGK has received research funding from AstraZeneca and research funding and consulting fees from Genentech and has represented AstraZeneca before the United States Food and Drug Administration. WP, VAM, MFZ, and HV, represented by the Sloan-Kettering Institute for Cancer Research, filed on June 1, 2004, a provisional patent application entitled “Use of mutations in EGFR kinase as an indicator of therapeutic efficacy of erlotinib in the treatment of NSCLC,” patent 60/576,275. HV is Co-founder and Chair of the Board of Directors of the Public Library of Science.

Author Contributions

WP conceived and designed the study; acquired, analyzed, and interpreted the data; and drafted the article and revised the manuscript. VAM conceived and designed the clinical aspects of the study, analyzed and interpreted the data, and helped draft the article. KAP helped design aspects of the study; acquired, analyzed, and interpreted the data; and helped draft the article. GJR helped acquire the clinical data and specimens and critically read the manuscript. RS designed and performed the cell viability studies and critically read the manuscript. MFZ acquired the pathologic data and critically read the manuscript. MGK helped acquire the clinical data and specimens and critically read the manuscript. HV contributed to the conception and design of the study and to the interpretation of the data, and edited the article and the revised manuscript.